PharmaTher Holdings Ltd.

CNSX: PHRM


Canadian symbol: PHRM.CN
US symbol: PHRRF

Currency in CAD

Valuation Measures4

Market Cap (intraday) 7.05M
Enterprise Value -3.09M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)N/A
Price/Book (mrq)0.83
Enterprise Value/Revenue N/A
Enterprise Value/EBITDA 0.64

Trading Information

Stock Price History

Beta (5Y Monthly) 2.17
52-Week Change 3-77.78%
S&P500 52-Week Change 3-13.12%
52 Week High 30.4200
52 Week Low 30.0800
50-Day Moving Average 30.1101
200-Day Moving Average 30.1448

Share Statistics

Avg Vol (3 month) 364.7k
Avg Vol (10 day) 323.39k
Shares Outstanding 588.17M
Implied Shares Outstanding 6N/A
Float 871.78M
% Held by Insiders 118.95%
% Held by Institutions 10.06%
Shares Short (Oct 13, 2022) 431.35k
Short Ratio (Oct 13, 2022) 40.4
Short % of Float (Oct 13, 2022) 4N/A
Short % of Shares Outstanding (Oct 13, 2022) 40.04%
Shares Short (prior month Sept 14, 2022) 424.32k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends May 30, 2022
Most Recent Quarter (mrq)Aug 30, 2022

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-38.27%
Return on Equity (ttm)-65.47%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -4.71M
Net Income Avi to Common (ttm)-4.88M
Diluted EPS (ttm)-0.0530
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)10.15M
Total Cash Per Share (mrq)0.12
Total Debt (mrq)N/A
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)70.26
Book Value Per Share (mrq)0.11

Cash Flow Statement

Operating Cash Flow (ttm)-4.37M
Levered Free Cash Flow (ttm)-2.54M

mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen



Warning: Use of undefined constant SITE_CONFIG_TWITTER_ACCOUNT - assumed 'SITE_CONFIG_TWITTER_ACCOUNT' (this will throw an Error in a future version of PHP) in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 10



Notice: Undefined variable: current_category_name in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 247

Psychedelics News and Psilocybin Investing

Real-time news from hundreds of sources. Never miss the news that matters the most.


Notice: Undefined index: newsCategory in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 363

Notice: Undefined index: stockNewsCategory in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 363



Company News Date
PHRM.CN
PharmaTher
10 months ago
PHRM.CN
PharmaTher
1 year ago
PHRM.CN
PharmaTher
1 year ago
PHRM.CN
PharmaTher
1 year ago

Notice: Undefined index: newsCategory in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/module-stock-news.php on line 710


Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626
Currency in CAD
Earnings EstimateCurrent Qtr. (Nov 2022)Next Qtr. (Feb 2023)Current Year (2023)Next Year (2024)
No. of Analysts1111
Avg. Estimate-0.01-0.02-0.07-0.11
Low Estimate-0.01-0.02-0.07-0.11
High Estimate-0.01-0.02-0.07-0.11
Year Ago EPS0-0.01-0.05-0.07
Revenue EstimateCurrent Qtr. (Nov 2022)Next Qtr. (Feb 2023)Current Year (2023)Next Year (2024)
No. of Analysts1111
Avg. EstimateN/AN/AN/AN/A
Low EstimateN/AN/AN/AN/A
High EstimateN/AN/AN/AN/A
Year Ago SalesN/AN/AN/AN/A
Sales Growth (year/est)N/AN/AN/AN/A
Earnings History2021-11-292022-02-272022-05-302022-08-30
EPS Est.-0.01-0.06-0.01-0.01
EPS Actual0-0.010-0.01
Difference0.010.050.010
Surprise %100.00%83.30%100.00%0.00%
EPS TrendCurrent Qtr. (Nov 2022)Next Qtr. (Feb 2023)Current Year (2023)Next Year (2024)
Current Estimate-0.01-0.02-0.07-0.11
7 Days Ago-0.01-0.02-0.07-0.11
30 Days Ago-0.01-0.02-0.07-0.11
60 Days Ago-0.01-0.02-0.07-0.11
90 Days Ago-0.01-0.02-0.07-0.11
EPS RevisionsCurrent Qtr. (Nov 2022)Next Qtr. (Feb 2023)Current Year (2023)Next Year (2024)
Up Last 7 DaysN/AN/AN/AN/A
Up Last 30 DaysN/AN/AN/AN/A
Down Last 7 DaysN/AN/AN/AN/A
Down Last 30 DaysN/AN/AN/AN/A
Growth EstimatesPHRM.CNIndustrySector(s)S&P 500
Current Qtr.N/AN/AN/AN/A
Next Qtr.-100.00%N/AN/AN/A
Current Year-40.00%N/AN/AN/A
Next Year-57.10%N/AN/AN/A
Next 5 Years (per annum)N/AN/AN/AN/A
Past 5 Years (per annum)N/AN/AN/AN/A

Notice: Undefined variable: insiders_html in /var/www/vhosts/shroominvestor.com/httpdocs/web/app/themes/15zine-child/template-company-details.php on line 711


Insiders transactions are updated every hour.

Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626

Major Holders

Currency in CAD
Breakdown
18.95%% of Shares Held by All Insider
0.06%% of Shares Held by Institutions
0.07%% of Float Held by Institutions
1Number of Institutions Holding Shares

Top Institutional Holders

HolderSharesDate Reported% OutValue
Captrust Financial Advisors1,000Jun 29, 20220.00%79
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by PharmaTher Holdings Ltd.


PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022

Nearly $12 million in cash and investment Fully funded for the Company’s development programs, including ketamine injection and infusion products, ketamine microneedle patch and ketamine wearable pump device for mental health, neurological, and pain disorders Seeking FDA approval for the Company’s ketamine injection and infusion products ... Read More...

PharmaTher Applies for FDA Orphan Drug Designation for Ketamine to Treat Rare Neurological Disorder Status Epilepticus

Adds to PharmaTher’s existing FDA orphan drug portfolio with amyotrophic lateral sclerosis and complex regional pain syndromeStrengthens commitment to treat rare disorders and life-threatening conditions with ketamine TORONTO, Nov. 24, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-... Read More...

PharmaTher Provides Business Update and Releases Financial Results for the First Quarter of Fiscal 2022

TORONTO, Oct. 27, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today released its business update and financial results for the three months ended August 31, 2021.  All amounts are stated in Canadian dollars unless otherwise indicated.   “To dat... Read More...

PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease

TORONTO, Oct. 06, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, announced today that it has initiated its Phase 2 KET-LID clinical trial of Ketamine for the treatment of Levodopa-Induced Dyskinesia in Subjects with Parkinson’s Disease. Patient sc... Read More...

PharmaTher Retains Former FDA Psychiatry Division Director Dr. Thomas Laughren as Regulatory Affairs Advisor

TORONTO, Sept. 29, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that Dr. Thomas Laughren has been retained by PharmaTher as a Regulatory Affairs Advisor. Dr. Laughren will advise on regulatory matters as it pertains to KETABET™, ... Read More...

PharmaTher Announces Closing of CAD$10 Million Private Placement with Institutional Investors

TORONTO, Sept. 28, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM)(OTCQB: PHRRF), a clinical-stage psychedelics biotech company, is pleased to announce that it has closed its previously announced private placement with institutional investors of its common shares (“Common Shares”) and warrants to purchase comm... Read More...

PharmaTher Announces CAD$10 Million Private Placement With Institutional Investors

NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICESOR FOR DISSEMINATION IN THE UNITED STATES TORONTO, Sept. 24, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (CSE: PHRM), a clinical-stage psychedelics biotech company, is pleased to announce that it has entered into a securities purchase agreement with institutional investors... Read More...

PharmaTher to Present at H.C. Wainwright 23rd Annual Global Investment Conference

To provide an update on PharmaTher’s product pipeline and upcoming milestones on its FDA Phase 2 clinical studies and microneedle patch programs involving ketamine and psychedelics TORONTO, Sept. 09, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, ... Read More...

PharmaTher Provides Business Highlights and Releases Annual Financials for Fiscal Year Ended May 31, 2021

TORONTO, Sept. 07, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today released business highlights and financial results for its fiscal year ended May 31, 2021. Unless otherwise indicated, all amounts in this press release are in Canadian dollar... Read More...

PharmaTher Expands Psychedelic Patent Portfolio with Filing of U.S. Patent Application for Novel Ketamine Formulation

Strengthens position to become a leader in the intradermal delivery of FDA prescription-based ketamine productsSupports commercializing novel uses and delivery methods of psychedelics TORONTO, July 21, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company... Read More...

PharmaTher To Participate in Grizzle Psychedelics Con

TORONTO, June 28, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that Fabio Chianelli, Chief Executive Officer, will participate in the Grizzle Psychedelics Con today at 12 PM ET. “I am very excited to participate in this one-of-a-... Read More...

PharmaTher To Present At The H.C. Wainwright Psychedelics In Psychiatry And Beyond Virtual Conference

TORONTO, June 16, 2021 -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that Fabio Chianelli, Chief Executive Officer, will be presenting at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17, 2021. Th... Read More...
Coming Soon.

Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626
IndexLast% Change
S&P 5003,998.841.79%Negative
Euro STOXX 503,956.53--
FTSE 1007,567.540.15%Positive
Nikkei 22527,906.200.31%Positive

Delayed data (1h)

Notice: A non well formed numeric value encountered in /var/www/vhosts/shroominvestor.com/httpdocs/web/functions_stocks.php on line 626
IndexLast% Change
S&P 5003,998.841.79%Negative
Euro STOXX 503,956.53--
FTSE 1007,567.540.15%Positive
Nikkei 22527,906.200.31%Positive


Share this page